

Joseph Jankovic

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6593861/joseph-jankovic-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

417
papers

20,987
citations

75
h-index

130
g-index

656
ext. papers

25,511
ext. citations

6.4
avg. IF

7.67
L-index

#	Paper	IF	Citations
417	The pharmacological treatment of Tourette syndrome. <i>International Review of Movement Disorders</i> , 2022 ,		
416	Association of Essential Tremor With Novel Risk Loci: A Genome-Wide Association Study and Meta-analysis.. <i>JAMA Neurology</i> , 2022 ,	17.2	3
415	Neurodegenerative diseases associated with non-coding CGG tandem repeat expansions.. <i>Nature Reviews Neurology</i> , 2022 ,	15	1
414	Head tremor in cervical dystonia: Quantifying severity with computer vision.. <i>Journal of the Neurological Sciences</i> , 2022 , 434, 120154	3.2	0
413	Coprolalia and Malignant Phonic Tics. <i>Current Clinical Neurology</i> , 2022 , 233-239	0.1	
412	Slowing Parkinson's Disease Progression with Vaccination and Other Immunotherapies.. <i>CNS Drugs</i> , 2022 , 36, 327	6.7	1
411	The clinical phenomenology and correlations of oculogyric tics.. <i>Acta Neurologica Belgica</i> , 2022 , 1	1.5	1
410	Dystonic motor and phonic tics in Tourette syndrome.. <i>Journal of Neurology</i> , 2022 , 1	5.5	1
409	Tremor 2022 , 305-331		
408	Tics and Tourette Syndrome 2022 , 99-140		
407	Parkinsonism 2022 , 395-413		
406	Efficacy and Safety of Fixed-Dose Deutetrabenazine in Children and Adolescents for Tics Associated With Tourette Syndrome: A Randomized Clinical Trial. <i>JAMA Network Open</i> , 2021 , 4, e2129397	10.4	3
405	Essential tremor. <i>Nature Reviews Disease Primers</i> , 2021 , 7, 83	51.1	2
404	Safety and Efficacy of Flexible-Dose Deutetrabenazine in Children and Adolescents With Tourette Syndrome: A Randomized Clinical Trial. <i>JAMA Network Open</i> , 2021 , 4, e2128204	10.4	3
403	Antiglutamic Acid Decarboxylase 65 Antibody-Associated Hemiataxia. <i>Neurology: Clinical Practice</i> , 2021 , 11, e564-e566	1.7	
402	Parkinson's disease after COVID-19. <i>Journal of the Neurological Sciences</i> , 2021 , 422, 117331	3.2	16
401	Quantitative mobility measures complement the MDS-UPDRS for characterization of Parkinson's disease heterogeneity. <i>Parkinsonism and Related Disorders</i> , 2021 , 84, 105-111	3.6	3

400	Increased Incidence of Functional (Psychogenic) Movement Disorders in Children and Adults Amid the COVID-19 Pandemic: A Cross-sectional Study. <i>Neurology: Clinical Practice</i> , 2021 , 11, e686-e690	1.7	22
399	Worldwide barriers to genetic testing for movement disorders. <i>European Journal of Neurology</i> , 2021 , 28, 1901-1909	6	2
398	Long-term efficacy and safety of botulinum toxin treatment for cervical dystonia: a critical reappraisal. <i>Expert Opinion on Drug Safety</i> , 2021 , 20, 695-705	4.1	3
397	Gene-Environment Interactions in Progressive Supranuclear Palsy. <i>Frontiers in Neurology</i> , 2021 , 12, 664796	4.1	1
396	Tourette Syndrome and Driving. <i>Movement Disorders Clinical Practice</i> , 2021 , 8, 763-768	2.2	1
395	Clinical-Instrumental patterns of neurodegeneration in Essential Tremor: A data-driven approach. <i>Parkinsonism and Related Disorders</i> , 2021 , 87, 124-129	3.6	3
394	A Multi-center Genome-wide Association Study of Cervical Dystonia. <i>Movement Disorders</i> , 2021 ,	7	2
393	Beyond tics: movement disorders in patients with Tourette syndrome. <i>Journal of Neural Transmission</i> , 2021 , 128, 1177-1183	4.3	4
392	Dystonia and Tremor: A Cross-Sectional Study of the Dystonia Coalition Cohort. <i>Neurology</i> , 2021 , 96, e563-e574	6.5	22
391	Parkinson's disease and skin. <i>Parkinsonism and Related Disorders</i> , 2021 , 82, 61-76	3.6	9
390	Tics and Tourette syndrome 2021 , 418-450.e15		
389	Head tremor and pain in cervical dystonia. <i>Journal of Neurology</i> , 2021 , 268, 1945-1950	5.5	5
388	Phenotypic Features of Isolated Essential Tremor, Essential Tremor Plus, and Essential Tremor-Parkinson's Disease in a Movement Disorders Clinic. <i>Tremor and Other Hyperkinetic Movements</i> , 2021 , 11, 12	2	10
387	Genome-Wide Association Study Meta-Analysis for Parkinson Disease Motor Subtypes. <i>Neurology: Genetics</i> , 2021 , 7, e557	3.8	4
386	Medical treatment of the motor features of Parkinson disease 2021 , 164-203.e14		1
385	Does Raising the Arms Modify Head Tremor Severity in Cervical Dystonia?. <i>Tremor and Other Hyperkinetic Movements</i> , 2021 , 11, 21	2	0
384	Quality of life in isolated dystonia: non-motor manifestations matter. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021 ,	5.5	6
383	Botulinum Neurotoxin Injections in Childhood Opisthotonus. <i>Toxins</i> , 2021 , 13,	4.9	5

382	Impulse Control Disorders in Parkinson's Disease: Epidemiology, Pathogenesis and Therapeutic Strategies. <i>Frontiers in Psychiatry</i> , 2021 , 12, 635494	5	3
381	Tremor Syndromes: An Updated Review. <i>Frontiers in Neurology</i> , 2021 , 12, 684835	4.1	12
380	Duration and onset of effect of incobotulinumtoxinA for the treatment of blepharospasm in botulinum toxin-naïve subjects. <i>Current Medical Research and Opinion</i> , 2021 , 37, 1761-1768	2.5	1
379	Exploring the role of botulinum toxin in critical care. <i>Expert Review of Neurotherapeutics</i> , 2021 , 21, 881-894	4.4	1
378	Predictive modeling of spread in adult-onset isolated dystonia: Key properties and effect of tremor inclusion. <i>European Journal of Neurology</i> , 2021 , 28, 3999-4009	6	1
377	The etiopathogenetic and pathophysiological spectrum of parkinsonism. <i>Journal of the Neurological Sciences</i> , 2021 , 120012	3.2	3
376	Parkinsonism and tremor syndromes. <i>Journal of the Neurological Sciences</i> , 2021 , 120018	3.2	1
375	Self-injurious behavior in Tourette syndrome. <i>Journal of Neurology</i> , 2021 , 1	5.5	3
374	Diagnostic criteria for blepharospasm: A multicenter international study. <i>Parkinsonism and Related Disorders</i> , 2021 , 91, 109-114	3.6	0
373	The Clinical Value of Patient Home Videos in Movement Disorders. <i>Tremor and Other Hyperkinetic Movements</i> , 2021 , 11, 37	2	2
372	Botulinum Toxin in Movement Disorders: An Update. <i>Toxins</i> , 2021 , 13,	4.9	27
371	Sports-Related Dystonia.. <i>Tremor and Other Hyperkinetic Movements</i> , 2021 , 11, 54	2	2
370	Stem Cells: Scientific and Ethical Quandaries of a Personalized Approach to Parkinson's Disease. <i>Movement Disorders</i> , 2020 , 35, 1312-1314	7	12
369	Outcome measurement in functional neurological disorder: a systematic review and recommendations. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020 , 91, 638-649	5.5	37
368	Parkinson's disease: etiopathogenesis and treatment. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020 , 91, 795-808	5.5	120
367	Treatment of Tardive Dyskinesia. <i>Neurologic Clinics</i> , 2020 , 38, 379-396	4.5	11
366	Treatment of tics associated with Tourette syndrome. <i>Journal of Neural Transmission</i> , 2020 , 127, 843-850	4.3	17
365	EASE LID 2: A 2-Year Open-Label Trial of Gocovri (Amantadine) Extended Release for Dyskinesia in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2020 , 10, 543-558	5.3	12

364	Parkinson disease and the immune system - associations, mechanisms and therapeutics. <i>Nature Reviews Neurology</i> , 2020 , 16, 303-318	15	105
363	152 Development of Deutetrabenazine as a Potential New Non-Antipsychotic Treatment for Tourette Syndrome in Children and Adolescents. <i>CNS Spectrums</i> , 2020 , 25, 297-297	1.8	2
362	Recent advances in understanding and treatment of Parkinson's disease. <i>Faculty Reviews</i> , 2020 , 9, 6	1.2	8
361	Deutetrabenazine in Tics Associated with Tourette Syndrome. <i>Tremor and Other Hyperkinetic Movements</i> , 2020 , 6, 422	2	41
360	Essential Tremor and Parkinson Disease: Exploring the Relationship. <i>Tremor and Other Hyperkinetic Movements</i> , 2020 , 8, 589	2	28
359	Postural Directionality and Head Tremor in Cervical Dystonia. <i>Tremor and Other Hyperkinetic Movements</i> , 2020 , 10,	2	6
358	It's tricky: Rating alleviating maneuvers in cervical dystonia. <i>Journal of the Neurological Sciences</i> , 2020 , 419, 117205	3.2	4
357	Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study. <i>Lancet Neurology</i> , 2020 , 19, 71-80	24.1	37
356	Genetic modifiers of risk and age at onset in GBA associated Parkinson's disease and Lewy body dementia. <i>Brain</i> , 2020 , 143, 234-248	11.2	69
355	Functional gait disorders, clinical phenomenology, and classification. <i>Neurological Sciences</i> , 2020 , 41, 911-915	3.5	13
354	Treatment of dystonia and tics. <i>Clinical Parkinsonism & Related Disorders</i> , 2020 , 2, 12-19	0.9	3
353	Essential tremor-plus: a controversial new concept. <i>Lancet Neurology</i> , 2020 , 19, 266-270	24.1	41
352	Outcome Measures for Functional Neurological Disorder: A Review of the Theoretical Complexities. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2020 , 32, 33-42	2.7	33
351	Expanding phenomenologic heterogeneity of tardive syndromes: Time for an updated assessment tool. <i>Parkinsonism and Related Disorders</i> , 2020 , 77, 141-145	3.6	0
350	Reply to: "Toward a Personalized Approach to Parkinson's Cell Therapy". <i>Movement Disorders</i> , 2020 , 35, 2120-2121	7	
349	Understanding the relationship between freezing of gait and other progressive supranuclear palsy features. <i>Parkinsonism and Related Disorders</i> , 2020 , 78, 56-60	3.6	4
348	A validation of a self-administered screening test for Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2020 , 418, 117116	3.2	1
347	Clinical and Demographic Characteristics of Upper Limb Dystonia. <i>Movement Disorders</i> , 2020 , 35, 2086-2090		3

346	Current Management of Tics and Tourette Syndrome: Behavioral, Pharmacologic, and Surgical Treatments. <i>Neurotherapeutics</i> , 2020 , 17, 1681-1693	6.4	31
345	Integrated sequencing and array comparative genomic hybridization in familial Parkinson disease. <i>Neurology: Genetics</i> , 2020 , 6, e498	3.8	5
344	Immunogenicity Associated with Botulinum Toxin Treatment. <i>Toxins</i> , 2019 , 11,	4.9	49
343	Minimal clinically important change in patients with cervical dystonia: Results from the CD PROBE study. <i>Journal of the Neurological Sciences</i> , 2019 , 405, 116413	3.2	7
342	Botulinum toxin for the treatment of tremor. <i>Parkinsonism and Related Disorders</i> , 2019 , 63, 31-41	3.6	20
341	Autosomal dominant mitochondrial membrane protein-associated neurodegeneration (MPAN). <i>Molecular Genetics & Genomic Medicine</i> , 2019 , 7, e00736	2.3	25
340	Young-onset Parkinson's disease: Its unique features and their impact on quality of life. <i>Parkinsonism and Related Disorders</i> , 2019 , 65, 39-48	3.6	23
339	Cervical dystonia: an update on therapeutics. <i>Expert Opinion on Orphan Drugs</i> , 2019 , 7, 199-209	1.1	
338	Clinical phenotype in carriers of intermediate alleles in the huntingtin gene. <i>Journal of the Neurological Sciences</i> , 2019 , 402, 57-61	3.2	14
337	Practice guideline recommendations summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders. <i>Neurology</i> , 2019 , 92, 896-906	6.5	154
336	Comprehensive systematic review summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders. <i>Neurology</i> , 2019 , 92, 907-915	6.5	91
335	Genetic Counseling in Huntington's Disease: Potential New Challenges on Horizon?. <i>Frontiers in Neurology</i> , 2019 , 10, 453	4.1	12
334	Head tremor at disease onset: an ataxic phenotype of cervical dystonia. <i>Journal of Neurology</i> , 2019 , 266, 1844-1851	5.5	20
333	Parkinson's disease age at onset genome-wide association study: Defining heritability, genetic loci, and β synuclein mechanisms. <i>Movement Disorders</i> , 2019 , 34, 866-875	7	136
332	Targeting β synuclein in Parkinson's Disease: Progress Towards the Development of Disease-Modifying Therapeutics. <i>Drugs</i> , 2019 , 79, 797-810	12.1	42
331	Pathogenesis and pathophysiology of functional (psychogenic) movement disorders. <i>Neurobiology of Disease</i> , 2019 , 127, 32-44	7.5	73
330	Hypertension and progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2019 , 66, 166-170	3.6	7
329	Juvenile parkinsonism: Differential diagnosis, genetics, and treatment. <i>Parkinsonism and Related Disorders</i> , 2019 , 67, 74-89	3.6	31

328	Are the International Parkinson disease and Movement Disorder Society progressive supranuclear palsy (IPMDS-PSP) diagnostic criteria accurate enough to differentiate common PSP phenotypes?. <i>Parkinsonism and Related Disorders</i> , 2019 , 69, 34-39	3.6	11
327	Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. <i>Lancet Neurology</i> , 2019 , 18, 1091-1102	24.1	562
326	[Essential tremor: genetic update]. <i>Expert Reviews in Molecular Medicine</i> , 2019 , 21, e8	6.7	13
325	Benefits and risks of unilateral and bilateral ventral intermediate nucleus deep brain stimulation for axial essential tremor symptoms. <i>Parkinsonism and Related Disorders</i> , 2019 , 60, 126-132	3.6	18
324	Levodopa-induced dyskinesias in mitochondrial membrane protein-associated neurodegeneration. <i>Neurology: Clinical Practice</i> , 2019 , 9, e7-e9	1.7	4
323	Pathogenesis-targeted therapeutic strategies in Parkinson's disease. <i>Movement Disorders</i> , 2019 , 34, 41-44		25
322	The Wide Spectrum of Functional Movement Disorders. <i>JAMA Neurology</i> , 2019 , 76, 235-236	17.2	1
321	Huntington disease: A quarter century of progress since the gene discovery. <i>Journal of the Neurological Sciences</i> , 2019 , 396, 52-68	3.2	36
320	Lifetime exposure to estrogen and progressive supranuclear palsy: Environmental and Genetic PSP study. <i>Movement Disorders</i> , 2018 , 33, 468-472	7	11
319	Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors. <i>Drugs</i> , 2018 , 78, 525-541	12.1	22
318	Parkinson's disease tremors and serotonin. <i>Brain</i> , 2018 , 141, 624-626	11.2	9
317	Tardive syndromes. <i>Journal of the Neurological Sciences</i> , 2018 , 389, 35-42	3.2	54
316	The nosology of tardive syndromes. <i>Journal of the Neurological Sciences</i> , 2018 , 389, 10-16	3.2	42
315	Onabotulinum toxin-A injections for sleep bruxism: A double-blind, placebo-controlled study. <i>Neurology</i> , 2018 , 90, e559-e564	6.5	34
314	The genetics of Parkinson disease. <i>Ageing Research Reviews</i> , 2018 , 42, 72-85	12	254
313	Leg stereotypy syndrome: phenomenology and prevalence. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018 , 89, 692-695	5.5	9
312	Autoimmune and paraneoplastic movement disorders: An update. <i>Journal of the Neurological Sciences</i> , 2018 , 385, 175-184	3.2	59
311	Cervical dystonia and substance abuse. <i>Journal of Neurology</i> , 2018 , 265, 970-975	5.5	8

310	Treatable inherited rare movement disorders. <i>Movement Disorders</i> , 2018 , 33, 21-35	7	57
309	An update on new and unique uses of botulinum toxin in movement disorders. <i>Toxicon</i> , 2018 , 147, 84-88	2.8	57
308	Botulinum Toxin for the Treatment of Hand Tremor. <i>Toxins</i> , 2018 , 10,	4.9	28
307	Atypical Alexander disease with dystonia, retinopathy, and a brain mass mimicking astrocytoma. <i>Neurology: Genetics</i> , 2018 , 4, e248	3.8	5
306	Medical treatment of blepharospasm. <i>Expert Review of Ophthalmology</i> , 2018 , 13, 233-243	1.5	2
305	Deutetrabenazine for the treatment of Huntington's chorea. <i>Expert Review of Neurotherapeutics</i> , 2018 , 18, 625-631	4.3	11
304	Local field potentials of subthalamic nucleus contain electrophysiological footprints of motor subtypes of Parkinson's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018 , 115, E8567-E8576	11.5	34
303	Consensus for the measurement of the camptocormia angle in the standing patient. <i>Parkinsonism and Related Disorders</i> , 2018 , 52, 1-5	3.6	27
302	Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti- α -Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinical Trial. <i>JAMA Neurology</i> , 2018 , 75, 1206-1214	17.2	144
301	The Role of TMEM230 Gene in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2018 , 8, 469-477	5.3	4
300	Essential Tremor and Parkinson's Disease: Exploring the Relationship. <i>Tremor and Other Hyperkinetic Movements</i> , 2018 , 8, 589	2	29
299	The Parkinson's progression markers initiative (PPMI) - establishing a PD biomarker cohort. <i>Annals of Clinical and Translational Neurology</i> , 2018 , 5, 1460-1477	5.3	142
298	Predictors of alcohol responsiveness in dystonia. <i>Neurology</i> , 2018 , 91, e2020-e2026	6.5	8
297	Ecopipam, a D1 receptor antagonist, for treatment of tourette syndrome in children: A randomized, placebo-controlled crossover study. <i>Movement Disorders</i> , 2018 , 33, 1272-1280	7	36
296	Dystonia. <i>Nature Reviews Disease Primers</i> , 2018 , 4, 25	51.1	117
295	Neuro-ophthalmology of movement disorders. <i>Expert Review of Ophthalmology</i> , 2018 , 13, 283-292	1.5	5
294	Movement disorders in 2016: Progress in Parkinson disease and other movement disorders. <i>Nature Reviews Neurology</i> , 2017 , 13, 76-78	15	21
293	Are psychogenic non-epileptic seizures just another symptom of conversion disorder?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017 , 88, 425-429	5.5	29

292	Diagnosis and Management of Parkinson's Disease. <i>Seminars in Neurology</i> , 2017 , 37, 118-126	3.2	61
291	Psychiatric associations of adult-onset focal dystonia phenotypes. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017 , 88, 595-602	5.5	52
290	A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease. <i>Neurology</i> , 2017 , 88, 152-159	6.5	75
289	ADCY5-related movement disorders: Frequency, disease course and phenotypic variability in a cohort of paediatric patients. <i>Parkinsonism and Related Disorders</i> , 2017 , 41, 37-43	3.6	54
288	Counseling At-Risk Parkinson Disease Cohorts: Integrating Emerging Evidence. <i>Current Genetic Medicine Reports</i> , 2017 , 5, 100-107	2.2	7
287	Thalamic DBS with a constant-current device in essential tremor: A controlled clinical trial. <i>Parkinsonism and Related Disorders</i> , 2017 , 40, 18-26	3.6	41
286	Apraclonidine in the treatment of ptosis. <i>Journal of the Neurological Sciences</i> , 2017 , 376, 129-132	3.2	19
285	Media hype: Patient and scientific perspectives on misleading medical news. <i>Movement Disorders</i> , 2017 , 32, 1319-1323	7	28
284	Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial. <i>JAMA Neurology</i> , 2017 , 74, 216-224	17.2	116
283	Distinguishing features of psychogenic (functional) versus organic hemifacial spasm. <i>Journal of Neurology</i> , 2017 , 264, 359-363	5.5	18
282	Examiner manoeuvres 'sensory tricks' in functional (psychogenic) movement disorders. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017 , 88, 453-455	5.5	6
281	Understanding falls in progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2017 , 35, 75-81	3.6	8
280	Parkinson disease: Exenatide - a drug for diabetes and Parkinson disease?. <i>Nature Reviews Neurology</i> , 2017 , 13, 643-644	15	13
279	Progress toward an integrated understanding of Parkinson's disease. <i>F1000Research</i> , 2017 , 6, 1121	3.6	17
278	Influences of HLA DRB1, DQA1 and DQB1 on T-cell recognition of epitopes and of larger regions of the botulinum neurotoxin molecule. <i>Immunology Letters</i> , 2017 , 190, 257-264	4.1	1
277	Available treatment options for dystonia. <i>Expert Opinion on Orphan Drugs</i> , 2017 , 5, 707-716	1.1	6
276	Statin-related musculoskeletal pain in Parkinson's disease. <i>Pain</i> , 2017 , 158, 1840	8	1
275	Botulinum toxin: State of the art. <i>Movement Disorders</i> , 2017 , 32, 1131-1138	7	118

274	Functional (psychogenic) stereotypies. <i>Journal of Neurology</i> , 2017 , 264, 1482-1487	5.5	12
273	Safety of Converting From Tetrabenazine to Deutetrabenazine for the Treatment of Chorea. <i>JAMA Neurology</i> , 2017 , 74, 977-982	17.2	96
272	Treatment of blepharospasm with apraclonidine. <i>Journal of the Neurological Sciences</i> , 2017 , 372, 57-59	3.2	11
271	Neuropsychological outcomes from constant current deep brain stimulation for Parkinson's disease. <i>Movement Disorders</i> , 2017 , 32, 433-440	7	34
270	Excessive burden of lysosomal storage disorder gene variants in Parkinson's disease. <i>Brain</i> , 2017 , 140, 3191-3203	11.2	209
269	Anosmia and Ageusia in Parkinson's Disease. <i>International Review of Neurobiology</i> , 2017 , 133, 541-556	4.4	53
268	Research Priorities in Limb and Task-Specific Dystonias. <i>Frontiers in Neurology</i> , 2017 , 8, 170	4.1	23
267	Dopamine depleters in the treatment of hyperkinetic movement disorders. <i>Expert Opinion on Pharmacotherapy</i> , 2016 , 17, 2461-2470	4	87
266	Genome-wide association study in essential tremor identifies three new loci. <i>Brain</i> , 2016 , 139, 3163-3169	11.2	57
265	Identification of TMEM230 mutations in familial Parkinson's disease. <i>Nature Genetics</i> , 2016 , 48, 733-9	36.3	122
264	Functional (psychogenic) saccadic oscillations and oculogyric crises. <i>Lancet Neurology</i> , 2016 , 15, 791	24.1	5
263	Movement disorders induced by deep brain stimulation. <i>Parkinsonism and Related Disorders</i> , 2016 , 25, 1-9	3.6	60
262	Parkinsonism, movement disorders and genetics in frontotemporal dementia. <i>Nature Reviews Neurology</i> , 2016 , 12, 175-85	15	80
261	New and emerging medical therapies in Parkinson's disease. <i>Expert Opinion on Pharmacotherapy</i> , 2016 , 17, 895-909	4	30
260	Psychogenic Ophthalmologic Movement Disorders. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2016 , 28, 195-8	2.7	13
259	Response to Shill and colleagues. <i>Parkinsonism and Related Disorders</i> , 2016 , 23, 108	3.6	
258	Botulinum Toxin for the Treatment of Tremor and Tics. <i>Seminars in Neurology</i> , 2016 , 36, 54-63	3.2	23
257	Submolecular recognition of the C-terminal domain of the heavy chain of botulinum neurotoxin type A by T cells from toxin-treated cervical dystonia patients. <i>Immunobiology</i> , 2016 , 221, 568-76	3.4	4

256	Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials. <i>JAMA Neurology</i> , 2016 , 73, 102-10	17.2	29
255	Whole-Exome Sequencing in Familial Parkinson Disease. <i>JAMA Neurology</i> , 2016 , 73, 68-75	17.2	52
254	The relationship between essential tremor and Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2016 , 22 Suppl 1, S162-5	3.6	73
253	Deutetrabenazine in Tics Associated with Tourette Syndrome. <i>Tremor and Other Hyperkinetic Movements</i> , 2016 , 6, 422	2	27
252	Recent Advances in Understanding and Managing Tourette Syndrome. <i>F1000Research</i> , 2016 , 5,	3.6	42
251	Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2016 , 316, 40-50	27.4	191
250	Clinimetric testing of the comprehensive cervical dystonia rating scale. <i>Movement Disorders</i> , 2016 , 31, 563-9	7	22
249	Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology. <i>Neurology</i> , 2016 , 86, 1818-26	6.5	291
248	Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia. <i>Drugs</i> , 2016 , 76, 759-77	12.1	66
247	Drug-Induced Dyskinesia, Part 2: Treatment of Tardive Dyskinesia. <i>Drugs</i> , 2016 , 76, 779-87	12.1	47
246	"Complex" dystonia is not a category in the new 2013 consensus classification. <i>Movement Disorders</i> , 2016 , 31, 1758-1759	7	4
245	Submolecular recognition regions of the H domain of the heavy chain of botulinum neurotoxin type A by T cells from toxin-treated cervical dystonia patients. <i>Journal of Neuroimmunology</i> , 2016 , 300, 36-46	3.5	6
244	Movement Disorders From the Use of Metoclopramide and Other Antiemetics in the Treatment of Migraine. <i>Headache</i> , 2016 , 56, 153-61	4.2	22
243	Earlier treatment of NMDAR antibody encephalitis in children results in a better outcome. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015 , 2, e130	9.1	73
242	Dopamine transporter imaging in essential tremor with and without parkinsonian features. <i>Journal of Neural Transmission</i> , 2015 , 122, 1515-21	4.3	18
241	Dopa-responsive dystonia--clinical and genetic heterogeneity. <i>Nature Reviews Neurology</i> , 2015 , 11, 414-24	14.5	142
240	Speech and voice disorders in patients with psychogenic movement disorders. <i>Journal of Neurology</i> , 2015 , 262, 2420-4	5.5	26
239	Epigenetic mechanisms in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2015 , 349, 3-9	3.2	83

238	Stiff-person syndrome: insights into a complex autoimmune disorder. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015 , 86, 840-8	5.5	105
237	Gait disorders. <i>Neurologic Clinics</i> , 2015 , 33, 249-68	4.5	36
236	Paroxysmal movement disorders. <i>Neurologic Clinics</i> , 2015 , 33, 137-52	4.5	48
235	Psychogenic movement disorders. <i>Neurologic Clinics</i> , 2015 , 33, 205-24	4.5	40
234	Movement disorders in catatonia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015 , 86, 825-32	5.5	26
233	Tetrabenazine in the treatment of Tourette syndrome. <i>Journal of Pediatric Neurology</i> , 2015 , 05, 009-013	0.2	3
232	Diffusion imaging of nigral alterations in early Parkinson's disease with dopaminergic deficits. <i>Movement Disorders</i> , 2015 , 30, 1885-92	7	40
231	Therapeutic Developments for Tics and Myoclonus. <i>Movement Disorders</i> , 2015 , 30, 1566-73	7	27
230	Clinical and scientific perspectives on movement disorders: Stanley Fahn's contributions. <i>Movement Disorders</i> , 2015 , 30, 1862-9	7	4
229	Rotenone affects p53 transcriptional activity and apoptosis via targeting SIRT1 and H3K9 acetylation in SH-SY5Y cells. <i>Journal of Neurochemistry</i> , 2015 , 134, 668-76	6	55
228	Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial. <i>Annals of Neurology</i> , 2015 , 78, 248-57	9.4	190
227	Effects of Auditory Rhythm and Music on Gait Disturbances in Parkinson's Disease. <i>Frontiers in Neurology</i> , 2015 , 6, 234	4.1	69
226	Clinical and pharmacological properties of incobotulinumtoxinA and its use in neurological disorders. <i>Drug Design, Development and Therapy</i> , 2015 , 9, 1913-26	4.4	21
225	Natural history of multiple system atrophy in the USA: a prospective cohort study. <i>Lancet Neurology</i> , 2015 , 14, 710-9	24.1	169
224	Restless legs syndrome: clinical presentation diagnosis and treatment. <i>Sleep Medicine</i> , 2015 , 16, 678-90	4.6	49
223	Genetics and molecular biology of brain calcification. <i>Ageing Research Reviews</i> , 2015 , 22, 20-38	12	23
222	A Pilot Study of a Cognitive-Behavioral Treatment for Anxiety and Depression in Patients With Parkinson Disease. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2015 , 28, 210-7	3.8	45
221	Primary results from the cervical dystonia patient registry for observation of onabotulinumtoxinA efficacy (CD PROBE). <i>Journal of the Neurological Sciences</i> , 2015 , 349, 84-93	3.2	52

220	The therapeutic potential of cannabinoids for movement disorders. <i>Movement Disorders</i> , 2015 , 30, 313-27		75
219	Symptomatic efficacy of rasagiline monotherapy in early Parkinson's disease: post-hoc analyses from the ADAGIO trial. <i>Parkinsonism and Related Disorders</i> , 2014 , 20, 640-3	3.6	27
218	The role of FUS gene variants in neurodegenerative diseases. <i>Nature Reviews Neurology</i> , 2014 , 10, 337-48	18.5	180
217	Sensory aspects of movement disorders. <i>Lancet Neurology</i> , 2014 , 13, 100-12	24.1	236
216	Bilateral pallidal deep brain stimulation for X-linked dystonia-parkinsonism. <i>World Neurosurgery</i> , 2014 , 82, 241.e1-4	2.1	15
215	Improvement in dystonic camptocormia following botulinum toxin injection to the external oblique muscle. <i>Parkinsonism and Related Disorders</i> , 2014 , 20, 1106-7	3.6	19
214	Copy number variation in obsessive-compulsive disorder and tourette syndrome: a cross-disorder study. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2014 , 53, 910-9	7.2	86
213	Neuroprotection by Orexin-A via HIF-1 α induction in a cellular model of Parkinson's disease. <i>Neuroscience Letters</i> , 2014 , 579, 35-40	3.3	51
212	Parkinson disease subtypes. <i>JAMA Neurology</i> , 2014 , 71, 499-504	17.2	310
211	Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2014 , 20, 142-8	3.6	69
210	Upper facial chorea in Huntington disease. <i>Journal of Clinical Movement Disorders</i> , 2014 , 1, 7	2.8	10
209	Long-term efficacy and safety of fluphenazine in patients with Tourette syndrome. <i>Movement Disorders</i> , 2014 , 29, 126-30	7	48
208	Genetic movement disorders in patients of Jewish ancestry. <i>JAMA Neurology</i> , 2014 , 71, 1567-72	17.2	21
207	The future of research in Parkinson disease. <i>JAMA Neurology</i> , 2014 , 71, 1351-2	17.2	24
206	Long-term efficacy, safety, and side effect profile of botulinum toxin in dystonia: a 20-year follow-up. <i>Toxicon</i> , 2014 , 90, 344-8	2.8	70
205	Chorea associated with Huntington's disease: to treat or not to treat?. <i>Movement Disorders</i> , 2014 , 29, 1414-8	7	39
204	Effects of long-term treatment with rotigotine transdermal system on dyskinesia in patients with early-stage Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2014 , 20, 1345-51	3.6	16
203	IncobotulinumtoxinA (Xeomin \textcircledR) injected for blepharospasm or cervical dystonia according to patient needs is well tolerated. <i>Journal of the Neurological Sciences</i> , 2014 , 346, 116-20	3.2	33

202	"Psychogenic" versus "functional" movement disorders? That is the question. <i>Movement Disorders</i> , 2014 , 29, 1697-8	7	19
201	Alleviating manoeuvres (sensory tricks) in cervical dystonia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014 , 85, 882-4	5.5	50
200	Progress in research on Tourette syndrome. <i>Journal of Obsessive-Compulsive and Related Disorders</i> , 2014 , 3, 359-362	1.7	20
199	Psychogenic tremor: a video guide to its distinguishing features. <i>Tremor and Other Hyperkinetic Movements</i> , 2014 , 4, 253	2	16
198	Observational Study of IncobotulinumtoxinA for Cervical Dystonia or Blepharospasm (XCiDaBLE): Interim Results for the First 170 Subjects with Blepharospasm. <i>Tremor and Other Hyperkinetic Movements</i> , 2014 , 4, 238	2	4
197	Medical treatment of dystonia. <i>Movement Disorders</i> , 2013 , 28, 1001-12	7	104
196	Sustained efficacy and safety of repeated incobotulinumtoxinA (Xeomin(®)) injections in blepharospasm. <i>Journal of Neural Transmission</i> , 2013 , 120, 1345-53	4.3	46
195	The VPS35 gene and Parkinson's disease. <i>Movement Disorders</i> , 2013 , 28, 569-75	7	64
194	Phenomenology and classification of dystonia: a consensus update. <i>Movement Disorders</i> , 2013 , 28, 863-73		1217
193	Long-term efficacy and safety of botulinum toxin injections in dystonia. <i>Toxins</i> , 2013 , 5, 249-66	4.9	61
192	Ask the Experts: Differentiating Parkinson's disease from other parkinsonian disorders 2013 , 136-140		
191	Tetrabenazine for treatment of chorea associated with Huntington's disease and other potential indications. <i>Expert Opinion on Orphan Drugs</i> , 2013 , 1, 423-436	1.1	13
190	Animal models of Parkinson's disease 2013 , 115-135		1
189	Effect of tetrabenazine on motor function in patients with huntington disease. <i>Neurology and Therapy</i> , 2012 , 1, 5	4.6	10
188	Deep brain stimulation for Tourette syndrome: target selection. <i>Stereotactic and Functional Neurosurgery</i> , 2012 , 90, 213-24	1.6	75
187	Paroxysmal Dyskinesias 2012 , 363-374		1
186	Secondary Dystonias 2012 , 135-145		
185	Other Tremors 2012 , 95-111		1

184	Acquired Chorea 2012 , 175-187		
183	Inherited and Sporadic Ataxias 2012 , 279-295		2
182	Clinical and Pathophysiological Features of Cerebellar Dysfunction 2012 , 257-278		3
181	Inherited Myoclonus Syndromes 2012 , 207-220		
180	Pathophysiology and Molecular Pathology of Dystonia and Tics 2012 , 15-25		
179	Psychogenic Movement Disorders 2012 , 375-384		2
178	Therapies in Parkinson's disease. <i>Current Opinion in Neurology</i> , 2012 , 25, 433-47	7.1	141
177	Segmental Myoclonus 2012 , 221-235		6
176	Overview of the Medical Treatment of the Non-Motor and Non-Dopaminergic Features of Parkinson's Disease 2011 , 394-408		
175	Flu-like symptoms following botulinum toxin therapy. <i>Toxicon</i> , 2011 , 58, 1-7	2.8	31
174	Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN [®] , botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia. <i>Journal of the Neurological Sciences</i> , 2011 , 308, 103-9	3.2	105
173	Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders. <i>Expert Review of Neurotherapeutics</i> , 2011 , 11, 1509-23	4.3	109
172	Rationale and design of a prospective study: Cervical Dystonia Patient Registry for Observation of OnaBotulinumtoxinA Efficacy (CD PROBE). <i>BMC Neurology</i> , 2011 , 11, 140	3.1	19
171	Tardive dyskinesia and other movement disorders secondary to aripiprazole. <i>Movement Disorders</i> , 2011 , 26, 147-52	7	64
170	Tourette syndrome: evolving concepts. <i>Movement Disorders</i> , 2011 , 26, 1149-56	7	154
169	Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin) in the treatment of blepharospasm-a randomized trial. <i>Movement Disorders</i> , 2011 , 26, 1521-8	7	56
168	Reply to: Treatment of tics in patients with Tourette syndrome: Recommendations according to the European Society for the Study of Tourette Syndrome. <i>Movement Disorders</i> , 2011 , 26, 2448-2448	7	10
167	Peripheral trauma and movement disorders: a systematic review of reported cases. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011 , 82, 892-8	5.5	73

166	Diagnosis and treatment of psychogenic parkinsonism. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011 , 82, 1300-3	5.5	38
165	Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. <i>Lancet Neurology, The</i> , 2010 , 9, 1164-1172	24.1	498
164	Tourette's syndrome in adults. <i>Movement Disorders</i> , 2010 , 25, 2171-5	7	50
163	Alcohol in essential tremor and other movement disorders. <i>Movement Disorders</i> , 2010 , 25, 2274-84	7	41
162	Treatment of hyperkinetic movement disorders. <i>Lancet Neurology, The</i> , 2009 , 8, 844-56	24.1	222
161	Relationship between various clinical outcome assessments in patients with blepharospasm. <i>Movement Disorders</i> , 2009 , 24, 407-13	7	92
160	Hemidystonia-hemiatrophy syndrome. <i>Movement Disorders</i> , 2009 , 24, 583-9	7	15
159	A double-blind, delayed-start trial of rasagiline in Parkinson's disease. <i>New England Journal of Medicine</i> , 2009 , 361, 1268-78	59.2	694
158	Disease-oriented approach to botulinum toxin use. <i>Toxicon</i> , 2009 , 54, 614-23	2.8	75
157	Unique properties of botulinum toxins. <i>Toxicon</i> , 2009 , 54, 675	2.8	3
156	Atomoxetine for freezing of gait in Parkinson disease. <i>Journal of the Neurological Sciences</i> , 2009 , 284, 177-8	3.2	34
155	Movement disorders. Preface. <i>Neurologic Clinics</i> , 2009 , 27, ix-x	4.5	1
154	Peripherally induced movement disorders. <i>Neurologic Clinics</i> , 2009 , 27, 821-32, vii	4.5	70
153	Parkinson's disease and movement disorders: moving forward. <i>Lancet Neurology, The</i> , 2008 , 7, 9-11	24.1	20
152	Surgical Treatments of Dystonia 2008 , 241-250		
151	Current approaches to the treatment of Parkinson's disease. <i>Neuropsychiatric Disease and Treatment</i> , 2008 , 4, 743-57	3.1	184
150	Reply: Autopsy-proven Huntington's disease with 29 trinucleotide repeats. <i>Movement Disorders</i> , 2008 , 23, 1793-1793	7	5
149	Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. <i>Movement Disorders</i> , 2008 , 23, 1353-60	7	158

148	Movement disorders in musicians. <i>Movement Disorders</i> , 2008 , 23, 1957-65	7	49
147	Distinguishing psychogenic and essential tremor. <i>Journal of the Neurological Sciences</i> , 2007 , 263, 94-9	3.2	74
146	Malignant Tourette syndrome. <i>Movement Disorders</i> , 2007 , 22, 1743-50	7	147
145	Candidate locus for chorea and tic disorders at 15q?. <i>Pediatric Neurology</i> , 2007 , 37, 70-3	2.9	12
144	Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease. <i>Archives of Neurology</i> , 2007 , 64, 676-82		118
143	Medical management of levodopa-associated motor complications in patients with Parkinson's disease. <i>CNS Drugs</i> , 2007 , 21, 677-92	6.7	141
142	Botulinum toxin therapy for cervical dystonia. <i>Neurotoxicity Research</i> , 2006 , 9, 145-8	4.3	76
141	Treatment of dystonia. <i>Lancet Neurology, The</i> , 2006 , 5, 864-72	24.1	245
140	Botulinum toxin treatment of facial myoclonus in suspected Rasmussen encephalitis. <i>Movement Disorders</i> , 2006 , 21, 1500-2	7	21
139	Genetic testing in Parkinson disease: promises and pitfalls. <i>Archives of Neurology</i> , 2006 , 63, 1232-7		57
138	Runner's dystonia. <i>Journal of the Neurological Sciences</i> , 2006 , 251, 73-6	3.2	74
137	Tourette's syndrome and the law. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2006 , 18, 86-95	2.7	23
136	Psychogenic tremor: long-term outcome. <i>CNS Spectrums</i> , 2006 , 11, 501-8	1.8	71
135	Tics associated with other disorders. <i>Advances in Neurology</i> , 2006 , 99, 61-8		14
134	An update on the treatment of Parkinson's disease. <i>Mount Sinai Journal of Medicine</i> , 2006 , 73, 682-9		20
133	Long-term botulinum toxin efficacy, safety, and immunogenicity. <i>Movement Disorders</i> , 2005 , 20, 592-7	7	187
132	Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations. <i>Movement Disorders</i> , 2005 , 20 Suppl 11, S11-6	7	350
131	Searching for a relationship between manganese and welding and Parkinson's disease. <i>Neurology</i> , 2005 , 64, 2021-8	6.5	135

130	Genetic mouse models of essential tremor: are they essential?. <i>Journal of Clinical Investigation</i> , 2005 , 115, 584-6	15.9	25
129	On secondary tics and tourettism. <i>Revista Brasileira De Psiquiatria</i> , 2005 , 27, 163-164	2.6	
128	Essential tremor among children. <i>Pediatrics</i> , 2004 , 114, 1203-5	7.4	62
127	Treatment of cervical dystonia with botulinum toxin. <i>Movement Disorders</i> , 2004 , 19 Suppl 8, S109-15	7	89
126	Evidence-based review of patient-reported outcomes with botulinum toxin type A. <i>Clinical Neuropharmacology</i> , 2004 , 27, 234-44	1.4	29
125	Dystonia: medical therapy and botulinum toxin. <i>Advances in Neurology</i> , 2004 , 94, 275-86		27
124	Reply: Reflex sympathetic syndrome and peripheral dystonia. <i>Movement Disorders</i> , 2003 , 18, 1213-1213	7	
123	Premonitory sensory phenomenon in Tourette's syndrome. <i>Movement Disorders</i> , 2003 , 18, 1530-3	7	226
122	Essential tremor: a heterogenous disorder. <i>Movement Disorders</i> , 2002 , 17, 638-44	7	157
121	Tremors 2002 , 513-522		
120	Levodopa strengths and weaknesses. <i>Neurology</i> , 2002 , 58, S19-32	6.5	75
119	Classification of paroxysmal dyskinesias and ataxias. <i>Advances in Neurology</i> , 2002 , 89, 387-400		31
118	Focal dystonia: the role of botulinum toxin. <i>Current Neurology and Neuroscience Reports</i> , 2001 , 1, 337-45	6.6	19
117	Novel mutation in the TOR1A (DYT1) gene in atypical early onset dystonia and polymorphisms in dystonia and early onset parkinsonism. <i>Neurogenetics</i> , 2001 , 3, 133-43	3	128
116	Dystonia in corticobasal degeneration. <i>Movement Disorders</i> , 2001 , 16, 252-7	7	65
115	Intrathecal baclofen for dystonia. <i>Movement Disorders</i> , 2001 , 16, 1201-2	7	77
114	Thalamic deep brain stimulation: effects on the nontarget limbs. <i>Movement Disorders</i> , 2001 , 16, 1137-42	7	29
113	Needle EMG guidance for injection of botulinum toxin. Needle EMG guidance is rarely required. <i>Muscle and Nerve</i> , 2001 , 24, 1568-70	3.4	54

112	Re-emergence of childhood stuttering in Parkinson's disease: a hypothesis. <i>Movement Disorders</i> , 2001 , 16, 114-8	7	39
111	Can peripheral trauma induce dystonia and other movement disorders? Yes!. <i>Movement Disorders</i> , 2001 , 16, 7-12	7	188
110	Are dopamine receptor agonists neuroprotective in Parkinson's disease?. <i>Drugs and Aging</i> , 2001 , 18, 389-96	7	60
109	Botulinum toxin for the treatment of cervical dystonia. <i>Expert Opinion on Pharmacotherapy</i> , 2001 , 2, 1985-94	7	17
108	Botulinum toxin in the treatment of tics. <i>Archives of Neurology</i> , 2000 , 57, 1190-3		163
107	Bruxism in Huntington's disease. <i>Movement Disorders</i> , 2000 , 15, 171-3	7	57
106	Hemifacial spasm and hypertension: how strong is the association?. <i>Movement Disorders</i> , 2000 , 15, 363-57		15
105	Niemann-Pick disease type C: two cases and an update. <i>Movement Disorders</i> , 2000 , 15, 1199-203	7	23
104	Gabapentin for essential tremor: a multiple-dose, double-blind, placebo-controlled trial. <i>Movement Disorders</i> , 2000 , 15, 678-82	7	120
103	Movement and reaction times and fine coordination tasks following pallidotomy. <i>Movement Disorders</i> , 1999 , 14, 57-62	7	41
102	Bilateral hemifacial spasm: a report of five cases and a literature review. <i>Movement Disorders</i> , 1999 , 14, 345-9	7	74
101	A novel sublingual apomorphine treatment for patients with fluctuating Parkinson's disease. <i>Movement Disorders</i> , 1999 , 14, 664-8	7	28
100	Movement and reaction times and fine coordination tasks following pallidotomy 1999 , 14, 57		1
99	Hemifacial spasm: clinical findings and treatment. <i>Muscle and Nerve</i> , 1998 , 21, 1740-7	3.4	261
98	Variability of the immunologic and clinical response in dystonic patients immunoresistant to botulinum toxin injections. <i>Movement Disorders</i> , 1998 , 13, 150-4	7	81
97	Evidence that a gene for essential tremor maps to chromosome 2p in four families. <i>Movement Disorders</i> , 1998 , 13, 972-7	7	111
96	Accuracy of the clinical diagnosis of postencephalitic parkinsonism: a clinicopathologic study. <i>European Journal of Neurology</i> , 1998 , 5, 451-457	6	35
95	Post-Traumatic Movement Disorders: Effect of the Legal System on Outcome. <i>Journal of Forensic Sciences</i> , 1998 , 43, 16143J	1.8	10

94	Familial essential tremor in 4 kindreds. Prospects for genetic mapping. <i>Archives of Neurology</i> , 1997 , 54, 289-94		44
93	Hemidystonia secondary to carotid artery gunshot injury. <i>Childs Nervous System</i> , 1997 , 13, 285-8	1.7	9
92	Cervical dystonia associated with tumors of the posterior fossa. <i>Movement Disorders</i> , 1997 , 12, 443-7	7	40
91	Tics secondary to craniocerebral trauma. <i>Movement Disorders</i> , 1997 , 12, 776-82	7	44
90	Botulinum toxin: Historical perspective and potential new indications. <i>Muscle and Nerve</i> , 1997 , 20, 129-145	14.5	113
89	Botulinum toxin: Historical perspective and potential new indications 1997 , 20, 129		12
88	Essential Tremor. <i>CNS Drugs</i> , 1996 , 6, 178-191	6.7	7
87	Botulinum toxin injection into vocal cord in the treatment of malignant coprolalia associated with Tourette's syndrome. <i>Movement Disorders</i> , 1996 , 11, 431-3	7	73
86	Severe motor tics causing cervical myelopathy in Tourette's syndrome. <i>Movement Disorders</i> , 1996 , 11, 563-6	7	99
85	Treatment of palatal myoclonus with sumatriptan. <i>Movement Disorders</i> , 1996 , 11, 748-51	7	49
84	Outcome after Stereotactic Thalamotomy for Dystonia and Hemiballismus. <i>Neurosurgery</i> , 1995 , 36, 501-508	5.8	121
83	Paroxysmal dyskinesias: clinical features and classification. <i>Annals of Neurology</i> , 1995 , 38, 571-9	9.4	462
82	Tourettism associated with Huntington's disease. <i>Movement Disorders</i> , 1995 , 10, 103-5	7	106
81	Case 1, 1995: psychosis, dementia, chorea, ataxia, and supranuclear gaze dysfunction. <i>Movement Disorders</i> , 1995 , 10, 257-62	7	21
80	International Classification of Diseases, tenth revision: neurological adaptation (ICD-10 NA): extrapyramidal and movement disorders. <i>Movement Disorders</i> , 1995 , 10, 533-40	7	21
79	Treatment of superficial siderosis of the central nervous system. <i>Movement Disorders</i> , 1995 , 10, 685	7	4
78	Muscle mitochondrial ATP production in progressive supranuclear palsy. <i>Journal of Neurochemistry</i> , 1994 , 62, 1631-4	6	32
77	Botulinum toxin in the treatment of dystonic tics. <i>Movement Disorders</i> , 1994 , 9, 347-9	7	106

76	What is it? Case 1, 1994: rapidly progressive aphasia, apraxia, dementia, myoclonus, and parkinsonism. <i>Movement Disorders</i> , 1994 , 9, 358-66	7	16
75	Movement disorders stereotactic surgery for Parkinson's disease. <i>Movement Disorders</i> , 1994 , 9, 470-2	7	7
74	A comparison of postspace-flight orthostatic intolerance to vasovagal syncope and autonomic failure and the potential use of the alpha agonist midodrine for these conditions. <i>Journal of Clinical Pharmacology</i> , 1994 , 34, 466-71	2.9	17
73	Hereditary motor-sensory neuropathy and movement disorders. <i>Muscle and Nerve</i> , 1993 , 16, 904-10	3.4	59
72	Cocaine-related movement disorders. <i>Movement Disorders</i> , 1993 , 8, 175-8	7	90
71	What is it? Case 1, 1993: parkinsonism, dysautonomia, and ophthalmoparesis. <i>Movement Disorders</i> , 1993 , 8, 525-32	7	16
70	Tardive tremor. <i>Movement Disorders</i> , 1992 , 7, 53-7	7	82
69	Persistent dystonia possibly induced by flecainide. <i>Movement Disorders</i> , 1992 , 7, 62-3	7	28
68	Stiff-person syndrome: an autoimmune disease. <i>Movement Disorders</i> , 1991 , 6, 12-20	7	118
67	Orthostatic tremor: an association with essential tremor. <i>Movement Disorders</i> , 1991 , 6, 60-4	7	61
66	Dystonic tics in patients with Tourette's syndrome. <i>Movement Disorders</i> , 1991 , 6, 248-52	7	74
65	Orthostatic tremor. <i>Movement Disorders</i> , 1991 , 6, 266-7	7	3
64	Sulpiride-induced tardive dystonia. <i>Movement Disorders</i> , 1990 , 5, 83-4	7	32
63	Dystonia and cerebellar ataxia. <i>Movement Disorders</i> , 1990 , 5, 178	7	12
62	Tardive akathisia: an analysis of clinical features and response to open therapeutic trials. <i>Movement Disorders</i> , 1989 , 4, 157-75	7	115
61	Lower body parkinsonism: evidence for vascular etiology. <i>Movement Disorders</i> , 1989 , 4, 249-60	7	210
60	Comparison of Sinemet CR4 and standard Sinemet: double blind and long-term open trial in parkinsonian patients with fluctuations. <i>Movement Disorders</i> , 1989 , 4, 303-9	7	41
59	Parkinsonism-plus syndromes. <i>Movement Disorders</i> , 1989 , 4 Suppl 1, S95-119	7	46

58	Abnormal systemic metabolism of iron, porphyrin, and calcium in Fahr's syndrome. <i>Annals of Neurology</i> , 1989 , 26, 569-75	9.4	31
57	Tardive dystonia in patients with Tourette's syndrome. <i>Movement Disorders</i> , 1988 , 3, 274-80	7	34
56	Case 2, 1988. Congenital mental retardation and juvenile parkinsonism. <i>Movement Disorders</i> , 1988 , 3, 352-61	7	5
55	Case 3, 1988. Progressive myoclonic epilepsy, dementia, and blindness in a young girl. <i>Movement Disorders</i> , 1988 , 3, 362-9	7	1
54	Progressive Supranuclear Palsy. <i>Canadian Journal of Neurological Sciences</i> , 1987 , 14, 547-554	1	39
53	Motor, behavioral and pharmacologic findings in Tourette's syndrome. <i>Canadian Journal of Neurological Sciences</i> , 1987 , 14, 541-6	1	89
52	Blepharospasm and autoimmune diseases. <i>Movement Disorders</i> , 1987 , 2, 159-63	7	44
51	Tardive myoclonus. <i>Movement Disorders</i> , 1987 , 2, 307-11	7	36
50	Parkinson's disease in monozygotic twins. <i>Annals of Neurology</i> , 1986 , 19, 405-8	9.4	11
49	The phenomenology of tics. <i>Movement Disorders</i> , 1986 , 1, 17-26	7	57
48	Parkinsonism and acquired hydrocephalus. <i>Movement Disorders</i> , 1986 , 1, 59-64	7	46
47	Association between essential tremor and Parkinson's disease. <i>Annals of Neurology</i> , 1985 , 17, 329-33	9.4	131
46	Low cancer rates among patients with Parkinson's disease. <i>Annals of Neurology</i> , 1985 , 17, 505-9	9.4	91
45	Blepharospasm and orofacial-cervical dystonia: clinical and pharmacological findings in 100 patients. <i>Annals of Neurology</i> , 1983 , 13, 402-11	9.4	293
44	Treatment of hyperkinetic movement disorders with tetrabenazine: a double-blind crossover study. <i>Annals of Neurology</i> , 1982 , 11, 41-7	9.4	140
43	Hereditary myoclonus and progressive distal muscular atrophy. <i>Annals of Neurology</i> , 1979 , 6, 227-31	9.4	26
42	The use of botulinum neurotoxin in tic disorders and essential hand and head tremor160-167		
41	Movement disorders of autoimmune origin52-72		1

- 40 Movement disorders associated with chronic metal poisoning 220-233
- 39 Movement disorders following non-metal intoxications 234-246
- 38 Dysautonomia in movement disorders 363-382
- 37 Gastrointestinal complications of movement disorders 383-397
- 36 Respiratory complications of movement disorders 398-418
- 35 Movement disorders in hematological disease 189-202
- 34 Drug-induced movement disorders 203-219
- 33 Movement disorders in stroke 247-267
- 32 Movement disorders in neoplastic brain disease 279-292 1
- 31 Movement disorders in renal diseases 172-188 1
- 30 Phenomenology, classification, and diagnostic approach to patients with movement disorders 1-15
- 29 Pathogenesis of movement disorders: basic neuroanatomy and pathophysiology 16-30
- 28 Principles of management in movement disorders 31-38
- 27 Paraneoplastic movement disorders 39-51
- 26 Movement disorders in systemic infections 73-88
- 25 Movement disorders in HIV- and AIDS-related central nervous system infections 89-98
- 24 Movement disorders in metabolic diseases in adulthood 99-114
- 23 Movement disorders in childhood metabolic diseases 115-130

- 22 Movement disorders in endocrinological diseases131-143 o
- 21 Movement disorders in multiple sclerosis268-278
- 20 The borderland between epilepsy and movement disorders333-351
- 19 Movement disorders in liver disease144-171
- 18 Movement disorders in encephalitis293-313
- 17 Sleep-related movement disorders314-332 2
- 16 Movement disorders associated with neuromuscular disorders and peripheral neuropathies352-362
- 15 Movement disorders emergencies419-441
- 14 Botulinum toxin: primary and secondary resistance45-57
- 13 Overview of the Medical Treatments of Hyperkinetic Disorders40-48
- 12 Other Jerks and Startles236-256
- 11 Pathophysiology and Molecular Pathology of Tremor, Myoclonus, and Chorea26-39
- 10 Tics and Tourette Syndrome188-199
- 9 Overview of Surgical Treatment Possibilities in Hyperkinetic Disorders49-69
- 8 Dyskinesias in Parkinsonian Syndromes297-310
- 7 Secondary Tics200-205
- 6 Stereotypies and Other Developmental Hyperkinesias353-362
- 5 Huntington Disease and Other Genetic Chorea147-174

4	Distinguishing Clinical Features of Hyperkinetic Disorders1-14	3
3	Tardive Dyskinesias331-352	3
2	Essential Tremor71-94	1
1	Primary Dystonias113-134	2